Leo Luznik

List of Publications by Citations

146 papers	8,876 citations	50 h-index	92 g-index
154 ext. papers	10,866 ext. citations	4.4 avg, IF	5.8 L-index

#	Paper	IF	Citations
146	HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 641-50	4.7	1168
145	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. *Blood*, **2015**, 126, 1033-40	2.2	431
144	HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. *Blood*, **2012**, 120, 4285-91	2.2	310
143	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. *Blood*, **2010**, 115, 3224-30	2.2	281
142	Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. *Blood*, **2001**, 98, 3456-64	2.2	242
141	Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. *Seminars in Oncology*, **2012**, 39, 683-93	5.5	217
140	Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. *Science Translational Medicine*, **2013**, 5, 211ra157	17.5	216
139	Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 1279-87	4.7	215
138	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. *Blood*, **2015**, 125, 3024-31	2.2	212
137	Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 482-9	4.7	207
136	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 211-234	4.7	206
135	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. *Blood*, **2012**, 119, 1570-80	2.2	178
134	Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. *Journal of Clinical Oncology*, **2014**, 32, 3497-505	2.2	175
133	Modern approaches to HLA-haploidentical blood or marrow transplantation. *Nature Reviews Clinical Oncology*, **2016**, 13, 10-24	19.4	169
132	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. *Journal of Clinical Oncology*, **2015**, 33, 3152-61	2.2	165
131	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. *Blood*, **2014**, 123, 3988-98	2.2	144
130	High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. *Immunologic Research*, **2010**, 47, 65-77	4.3	139

129	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. *Nature Medicine*, **2019**, 25, 603-611	50.5	136
128	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. *Journal of Clinical Investigation*, **2014**, 124, 4867-76	15.9	132
127	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. *Blood*, **2014**, 124, 3817-27	2.2	128
126	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. *Haematologica*, **2017**, 102, 391-400	6.6	119
125	Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. *Blood*, **2014**, 124, 2131-41	2.2	111
124	Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1404-9	4.7	107
123	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. *Blood*, **2018**, 131, 247-262	2.2	105
122	Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. *Seminars in Hematology*, **2016**, 53, 90-7	4	96
121	The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. *Bone Marrow Transplantation*, **2018**, 53, 521-534	4.4	94
120	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. *Blood*, **2016**, 127, 2144-54	2.2	94
119	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. *Blood*, **2010**, 115, 2136-41	2.2	91
118	Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. *Biology of Blood and Marrow Transplantation*, **2002**, 8, 131-8	4.7	90
117	Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 647-52	4.7	86
116	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. *Science Translational Medicine*, **2015**, 7, 288ra78	17.5	85
115	Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. *Cancer Immunology, Immunotherapy*, **2010**, 59, 137-48	7.4	83
114	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. *Blood*, **2017**, 129, 2570-2580	2.2	82
113	HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 314-8	4.7	81
112	Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1514-7	4.7	80

111	Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. *Cancer Control*, **2002**, 9, 123-37	2.2	80
110	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. *Blood*, **2016**, 128, 1013-7	2.2	77
109	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. *Blood*, **2015**, 125, 4085-94	2.2	76
108	Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. *JCI Insight*, **2016**, 1,	9.9	76
107	Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 602-6	4.7	71
106	High-dose cyclophosphamide for graft-versus-host disease prevention. *Current Opinion in Hematology*, **2010**, 17, 493-9	3.3	71
105	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. *JCI Insight*, **2018**, 3,	9.9	70
104	STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. *Journal of Immunology*, **2010**, 184, 764-74	5.3	66
103	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. *Lancet Haematology,the*, **2019**, 6, e183-e193	14.6	62
102	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. *Journal of Hematology and Oncology*, **2016**, 9, 35	22.4	62
101	Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. *Blood*, **2003**, 101, 1645-52	2.2	59
100	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. *Blood Advances*, **2017**, 1, 288-292	7.8	58
99	Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. *Mental Illness*, **2011**, 3 Suppl 2, e15	0.9	56
98	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. *Blood Advances*, **2017**, 1, 652-661	7.8	55
97	5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 754-8	4.7	54
96	Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 414-21	4.7	50
95	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. *Clinical Cancer Research*, **2018**, 24, 3519-3527	12.9	49
94	Sustained CD4 T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. *OncoImmunology*, **2014**, 3, e27357	7.2	49

93	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. *Blood*, **2017**, 129, 1389-1393	2.2	46
92	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 343-352	4.7	46
91	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 325-332	4.7	46
90	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2020**, 55, 12-24	4.4	46
89	Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. *Blood*, **2011**, 117, 608-17	2.2	41
88	Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. *Blood Advances*, **2020**, 4, 1770-1779	7.8	39
87	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1099-1102	4.7	39
86	OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. *European Journal of Haematology*, **2016**, 96, 27-35	3.8	36
85	Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. *Journal of Immunology*, **2006**, 177, 4414-25	5.3	34
84	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1274-1280	4.7	32
83	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. *Current Drug Targets*, **2017**, 18, 315-331	3	32
82	Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8 T Cells During Relapse after Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 666-677	4.7	30
81	The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 499-509	4.7	29
80	Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2431-2437	4.7	28
79	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 112-8	4.7	27
78	Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1887-1894	4.7	25
77	How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. *Blood*, **2019**, 134, 1802-1810	2.2	25
76	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. *Haematologica*, **2020**, 105, 47-58	6.6	25

75	Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. *Blood*, **2016**, 127, 352-9	2.2	24
74	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2056-2064	4.7	24
73	ExpertsPconsiderations on HLA-haploidentical stem cell transplantation. *European Journal of Haematology*, **2014**, 93, 187-97	3.8	23
72	Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide. *Haematologica*, **2017**, 102, 932-940	6.6	21
71	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 2115-2122	4.7	21
70	Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. *Blood*, **2007**, 109, 4564-74	2.2	21
69	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1128-1135	4.7	21
68	Immune reconstitution after T-cell replete HLA-haploidentical transplantation. *Seminars in Hematology*, **2019**, 56, 221-226	4	20
67	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. *Blood Advances*, **2020**, 4, 3913-3925	7.8	20
66	Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. *Bone Marrow Transplantation*, **2020**, 55, 40-47	4.4	19
65	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1022-1028	4.7	17
64	Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent. *OncoImmunology*, **2015**, 4, e974393	7.2	14
63	National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. *Journal of Clinical Oncology*, **2021**, 39, 1971-1982	2.2	14
62	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. *Blood*, **2019**, 133, 94-99	2.2	14
61	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 612-617	4.7	13
60	Have haploidentical transplants replaced umbilical cord transplants for acute leukemias?. *Current Opinion in Hematology*, **2018**, 25, 103-111	3.3	13
59	Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. *Seminars in Hematology*, **2015**, 52, 232-42	4	12
58	Systemic depletion of lymphocytes following focal radiation to the brain in a murine model. *OncoImmunology*, **2018**, 7, e1445951	7.2	10

57	Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1903-1909	4.7	10
56	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. *Blood Advances*, **2019**, 3, 2581-2585	7.8	10
55	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. *Leukemia and Lymphoma*, **2016**, 57, 666-75	1.9	9
54	Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity. *Transplantation*, **2007**, 83, 631-40	1.8	9
53	Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,. *Blood*, **2011**, 118, 4151-4151	2.2	9
52	T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 868-882	4.7	8
51	Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1679-1688	4.7	8
50	Post-transplantation cyclophosphamide for chimerism-based tolerance. *Bone Marrow Transplantation*, **2019**, 54, 769-774	4.4	8
49	Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies. *Biology of Blood and Marrow Transplantation*, **2015**, 21, S29	4.7	8
48	Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. *Journal of Clinical Investigation*, **2019**, 129, 2189-2191	15.9	8
47	Targeting PI3K□function for amelioration of murine chronic graft-versus-host disease. *American Journal of Transplantation*, **2019**, 19, 1820-1830	8.7	8
46	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. *Blood*, **2020**, 135, 28-40	2.2	8
45	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. *Blood Cancer Discovery*, **2021**, 2, 616-629	7	8
44	Comparable and Robust Immune Reconstitution after HLA-Haploidentical or HLA-Matched Allogeneic Transplantation (BMT) Utilizing Posttransplantation Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2015**, 21, S71	4.7	7
43	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. *Leukemia*, **2020**, 34, 1563-1576	10.7	7
42	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. *Transplantation and Cellular Therapy*, **2021**, 27, 452-466		7
41	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. *Blood Advances*, **2019**, 3, 2608-2616	7.8	7
40	Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. *Frontiers in Immunology*, **2020**, 11, 636	8.4	6

39	New treatment approaches in acute myeloid leukemia: review of recent clinical studies. *Reviews on Recent Clinical Trials*, **2012**, 7, 224-37	1.2	6
38	Hormone Receptor Regulation of the Human Immunodeficiency Virus Type 1 and Type 2 Long Terminal Repeats. *Journal of Biomedical Science*, **1996**, 3, 323-331	13.3	6
37	How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. *Hematology American Society of Hematology Education Program*, **2019**, 2019, 513-521	3.1	6
36	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. *Lancet HIV,the*, **2020**, 7, e602-e610	7.8	6
35	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. *Blood Advances*, **2020**, 4, 5078-5088	7.8	6
34	Teaching a Young Dog New Tricks: Modifications to the Post-Transplantation Cyclophosphamide Haploidentical Transplantation Platform. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1108-1110	4.7	5
33	Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen. *Transplantation*, **2016**, 100, e140-e146	1.8	5
32	Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma. *Leukemia and Lymphoma*, **2013**, 54, 655-7	1.9	5
31	Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 502-508	4.7	5
30	Might haplo "be the (better) match"?. *Blood*, **2016**, 127, 799-800	2.2	5
29	Rarity of Donor-Derived Malignancy after Allogeneic BMT with High-Dose Post-Transplantation Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2014**, 20, S252	4.7	4
28	Desensitization for Mismatched Hematopoietic Stem Cell Transplantation (HSCT). *Blood*, **2011**, 118, 1955-1955	2.1	4
27	Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy). *Blood*, **2014**, 124, 730-730	2.2	4
26	Signatures of GVHD and Relapse after Post-Transplant Cyclophosphamide Revealed by Immune Profiling and Machine Learning. *Blood*, **2021**,	2.2	4
25	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. *Journal of Clinical Oncology*, **2021**, JCO2102293	2.2	4
24	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 2075-2081	4.7	4
23	Are alternative donors really still "alternative?". *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1463-4	4.7	3
22	Nonmyeloablative alternative donor transplants. *Current Opinion in Oncology*, **2003**, 15, 121-6	4.2	3

21	Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).. *Blood*, **2007**, 110, 173-173	2.2	3
20	Critical Role of CD4+Foxp3+ T Cells In Gvhd Prevention with High-Dose Posttransplant Cyclophosphamide (Cy).. *Blood*, **2010**, 116, 3749-3749	2.2	3
19	Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 2306-2310	4.7	3
18	Treatment of AML Relapse After Allo-HCT.. *Frontiers in Oncology*, **2021**, 11, 812207	5.3	3
17	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. *Blood*, **2014**, 124, 535-535	2.2	2
16	A Selective and Potent Rock 2 Inhibitor (KD025) Decreases Human STAT3-Dependent IL-21 and IL-17 Production and Experimental Chronic Graft-Versus-Host Disease (cGVHD). *Blood*, **2014**, 124, 540-540	2.2	2
15	PTCY keeps on giving!. *Blood*, **2019**, 134, 848-849	2.2	2
14	Post-Transplantation High Dose Cyclophosphamide (Cy) Is Effective Single Agent for Prevention of Acute and Chronic Graft Versus Host Disease after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). *Blood*, **2008**, 112, 56-56	2.2	1
13	Post-Transplant Cyclophosphamide and Sirolimus Are Synergistic in Preventing Rejection and Inducing Stable Mixed Chimerism Independently of Regulatory T Cells.. *Blood*, **2009**, 114, 3540-3540	2.2	1
12	Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity. *Journal of Immunotherapy*, **2019**, 42, 73-80	5	1
11	Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. *Transplantation and Cellular Therapy*, **2021**, 27, 1021.e1-1021.e1		1
10	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. *Transplantation and Cellular Therapy*, **2021**, 27, 863.e1-863.e5		1
9	PTCy and "The Story of the Three Bears". *Bone Marrow Transplantation*, **2021**, 56, 765-766	4.4	0
8	Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide. *Transplantation and Cellular Therapy*, **2021**, 27, 909.e1-909.e6		0
7	Haploidentical Transplants: Immune Reconstitution With and Without Augmentation Strategies **2018**, 271-289		
6	For Whom the Bell Tolls: Programmed Death 1 as a Marker of Post-Transplantation Mortality. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2115-2116	4.7	
5	Hematopoietic Stem Cell Transplantation for Cancer **2017**, 284-292		
4	Notching up B-cell pathology in chronic GVHD. *Blood*, **2017**, 130, 2053-2054	2.2	

3	Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia. *Blood*, **2021**, 138, 223-223	2.2
2	STAT3 Signaling in Donor-Derived CD4+ T-Cells Plays a Critical Role in the Induction of Acute and Chronic GVHD in Murine Models of alloBMT.. *Blood*, **2007**, 110, 2179-2179	2.2
1	Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia. *Blood*, **2014**, 124, 1065-1065	2.2